National Bank of Canada
CRDL

National Bank of Canada’s Cardiol Therapeutics CRDL Stock Holding History

National Bank of Canada’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.14K Buy
2,323
+622
+37% +$638 ﹤0.01% 2547
2025
Q4 		$1.61K Buy
1,701
+135
+9% +$141 ﹤0.01% 2585
2025
Q3 		$1.7K Sell
1,566
-7,647
-83% -$9.28K ﹤0.01% 2605
2025
Q2 		$12.5K Buy
9,213
+650
+8% +$757 ﹤0.01% 2292
2025
Q1 		$8.15K Buy
8,563
+2,678
+46% +$3.29K ﹤0.01% 2290
2024
Q4 		$7.58K Buy
5,885
+5,683
+2,813% +$9.58K ﹤0.01% 2387
2024
Q3 		$400 Sell
202
-1,798
-90% -$3.73K ﹤0.01% 2491
2024
Q2 		$3.94K Sell
2,000
-120
-6% -$255 ﹤0.01% 2312
2024
Q1 		$4.51K Buy
2,120
+120
+6% +$162 ﹤0.01% 2331
2023
Q4 		$1.76K Hold
2,000
– – ﹤0.01% 2474
2023
Q3 		$1.7K Hold
2,000
– – ﹤0.01% 2529
2023
Q2 		$1.75K Hold
2,000
– – ﹤0.01% 2489
2023
Q1 		$977 Buy
+2,000
New +$1.18K ﹤0.01% 2533

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

National Bank of Canada's CRDL Position: Q1 2026 in Review

National Bank of Canada increased its Cardiol Therapeutics (CRDL) stake by 37% in Q1 2026, buying an estimated $638 and bringing the position to 2,323 shares worth $3.14K. The position accounts for ﹤0.01% of the portfolio, ranked #2547.

National Bank of Canada first reported a position in CRDL in Q1 2023 and has held it in 13 quarters since. The position peaked at $12.5K in Q2 2025. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • National Bank of Canada held 2,323 shares of Cardiol Therapeutics worth $3.14K as of Q1 2026.
  • National Bank of Canada bought 622 Cardiol Therapeutics shares in Q1 2026, an estimated $638.
  • Cardiol Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2547 holding.
  • National Bank of Canada first reported a position in Cardiol Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • National Bank of Canada's Cardiol Therapeutics position peaked at $12.5K in Q2 2025.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.